C4X.F Onxeo SA

Healthcare Biotechnology Frankfurt Exchange
0.4600 EUR
Close of Nov 11, 2026
0.0910 0.9300
Market cap
EUR 270M
P/E
-
P/B
115.66x
ROE
-236.0%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is C4X.F undervalued?

Graham number

The Graham number of Onxeo SA cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Onxeo SA fundamental analysis

No fundamental analysis for Onxeo SA yet.

Onxeo SA stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Onxeo SA

Valerio Therapeutics Société anonyme, a clinical-stage biotechnology company, develops technology platforms dedicated to the targeted delivery of therapies. The company develops PlatON, a proprietary chemical platform for DNA decoy therapies, which generates new compounds and broadens its product portfolio; DecoyTAC, a mechanism of action of DNA decoy therapies coupled with targeted protein degradation; and V-body platform, a bispecific T-cell engagers, antibody" drug conjug…

Full company profile